CA Patent

CA2449054C — Integrin targeting liposome for nucleic acid delivery

Assigned to Scripps Research Institute · Expires 2011-01-04 · 15y expired

What this patent protects

.alpha.v.beta.3 Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic .alpha.v.beta.3 integrin antagonist.

USPTO Abstract

.alpha.v.beta.3 Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic .alpha.v.beta.3 integrin antagonist.

Drugs covered by this patent

Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb

Patent Metadata

Patent number: CA2449054C
Jurisdiction: CA
Classification: —
Expires: 2011-01-04
Drug substance claim: No
Drug product claim: No
Assignee: Scripps Research Institute
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.